Andrew Huberman· PhD
So either, typically it's a high dose psilocybin, or three dose, as I saw it for the MAP study of MDMA.
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
So either, typically it's a high dose psilocybin, or three dose, as I saw it for the MAP study of MDMA.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
Having said that, there are clinical studies showing, and these are small studies and they're short duration, small number of subjects, but taking people, for example, who are addicted to alcohol and then having them have this, let's say psychedelic experience in a very controlled setting.